Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer
- 18 December 2015
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (1) , 2-5
Abstract
In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clinical outcomes. However, the emergence of a newly discovered acquired drug resistance challenges the concept of small molecule targeted cancer therapy in NSCLC.Keywords
This publication has 12 references indexed in Scilit:
- Abstract 793: Insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical modelsCancer Research, 2015
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 2013
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksJournal of Medicinal Chemistry, 2012
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialThe Lancet Oncology, 2012
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Structural insights into how irreversible inhibitors can overcome drug resistance in EGFRBioorganic & Medicinal Chemistry, 2008
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004